Fulcrum Therapeutics moved to sharply reduce operations after discontinuing development of its sickle cell disease candidate pociredir, citing an FDA assessment of the drug’s benefit-risk profile. In an SEC filing, the company said it would cut 85% of staff, reducing headcount to nine full-time employees, and pursue strategic alternatives after the regulatory stop.